Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

TECHNIVIE

OMBITASVIR; PARITAPREVIR; RITONAVIR

Standard Dose
12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview TECHNIVIE is listed in Drugs@FDA under application 207931 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient OMBITASVIR; PARITAPREVIR; RITONAVIR Form and strength TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBVIE Submission history Latest submission status date: 2019-12-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview TECHNIVIE is listed in Drugs@FDA under application 207931 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient OMBITASVIR; PARITAPREVIR; RITONAVIR Form and strength TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBVIE Submission history Latest submission status date: 2019-12-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.